ESRRB and breast carcinoma: One of the best molecular markers of dormancy is the orphan nuclear receptor NR2F142,43, a member of the retinoic acid receptor family43 that has been shown to be a marker for cancer dormancy in pre-clinical models and cancer patients, as well to be an independent prognostic indicator for time-to-distant-recurrence in breast cancer patients42.